ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Investor Presentation (June 2010)

24 slides from ThermoGenesis's investor presentation, June 2010

  1. Slide 1: ThermoGenesis Corp. Investor Presentation

    ThermoGenesis Corp. Investor Presentation June 2010 1 Revision #1

  2. Slide 2: Safe Harbor

    Safe Harbor Certain matters discussed in this presentation are "forward-looking statements." These forward-looking statements can generally be identified as by the context of the statement that includes words such as the Company "expects expects," "anticipates" anticipates or words of similar import

  3. Slide 3: ThermoGenesis: Mission & Business Model

    ThermoGenesis: Mission & Business Model • Mission: Design, develop and commercialize cell processing products that enable the practice of regenerative g medicine through g the collection,, separation and storage of adult stem cells • Business B i Model: M d l The Th sale l off medical di l devices d

  4. Slide 4: ThermoGenesis: Momentum Strong

    ThermoGenesis: g Momentum Strong • Technology gy leader for collection/processing /p g of stem cells from cord blood/bone marrow • Solid customer base (largest worldwide private, and largest U.S. public cord blood bank under contract) • Recent new product introductions in growing bone marrow segment

  5. Slide 5: New Leadership, New Focus

    New Leadership, New Focus Name Position Experience J. Melville Engle CEO, Director Dey L.P. , Anika, Allergan Matthew T. Plavan EVP, COO, CFO McKesson, StrionAir, Reason Inc Hal Baker VP, Commercial Operations Pall, Caridian, BCT Jorge Artiles Chief Quality/Regulatory Officer Medtronic, Baxter, Abbo

  6. Slide 6: Growth Strategy

    Growth Strategy • Achieve top line growth, operating efficiencies g • Ride the wave of regenerative market expansion p • Insist on highest product quality to delight our customers gp • Continue existing product g growth • Launch new products and develop new indications with existing products • Partn

  7. Slide 7: Recent Accomplishments

    Recent Accomplishments • Signed global Res-Q™ 60 BMC (Res-Q) Distribution Agreement with GE Healthcare • Submitted 510(k) for Res-Q PRP in February • Signed new Distribution Agreement to extend global reach for bone marrow products d t ini Asia A i and d Central/South C t l/S th America A i • Sign N

  8. Slide 8: U.S. Regenerative Medicine Market: Poised for Significant Growth

    U.S. Regenerative Medicine Market: Poised for Significant Growth Other 1% Orthopedic Indications Nerve Repair 19% 36% Cardio-vascular 29% Anti- Inflammatory 8% Source: Robyn Young, Stem Cell Summit, 2009, pg. 16: U.S. market: $8.1 billion by 2018 8

  9. Slide 9: Our Key Product Lineup

    Our Key Product Lineup Cord Blood • AXP – Cord Blood Stem Cell Banking • Manual Processing – Cord Blood Stem Cell Banking • BioArchive – Stem Cell Cryopreservation and Storage Bone Marrow • MXP™ MarrowXpress™ (MXP) – Laboratory Stem Cell Processing g • Res-Q – Point-of-Care Stem Cell Processing 9

  10. Slide 10: Cord Blood Processing Market ($55M) and Share

    Cord Blood Processing Market ($55M) and Share Dual Sites Public Private (Public & Total Private) Total number of CBB 170 215 13 398 Number of CB Processing Banks 132 146 13 291 Annual Collections-Market - Automated 45,000 142,000 13,600 200,600 - Manual 23,000 150,000 88,600 261,600 Total 68,000 292

  11. Slide 11: Cord Blood Storage Market ($37M) and Share

    Cord Blood g Market ($ Storage ($37M) ) and Share Public Private Total No. of Cord Banks 177 221 398 No of Storage Banks No. 143 153 296 Storage Market Size $16M $21M $37M ($) BioArchive Customers 76 26 102 BioArchive Customer 53% 17% 52% Share Source: ThermoGenesis estimate for 2010 11

  12. Slide 12: AXP Cord Blood Product Description

    AXP Cord Blood Product Description • The most innovative automated cell capture and isolation system on the market (device and disposables) • Avoids contamination risk • cGMP compliant data management Highest Stem Cell Yield* Automated AXP (-HES) ~ 98%* Easil Scalable Easily Manual HES ~ 81.5% • Ind

  13. Slide 13: BioArchive Product Description

    BioArchive Product Description • State-of-the-art stem cell storage system • Controlled rate freezing – 1-2C/min • Correct storage temperature - 196C • Minimum transient warming events Preserves Cell Viability CFU-C Recovery 96± 4.8% Source: Dobrila et al. “ThermoGenesis AXP and BioArchive Systems f

  14. Slide 14: GE Healthcare

    GE Healthcare • AXP distribution in U.S. and approximately 30 countries throughout the world • Contract extended February 1, 2010, expires July 31, 2012 (renewable) • Significant increase in GEHC sales & marketing funding • Revitalized collaborative sales effort with ThermoGenesis: one face to the c

  15. Slide 15: MXP Bone Marrow Product Description

    MXP Bone Marrow Product Description • AXP derivative • Automated laboratory processing of stem cells from bone marrow (device ( and disposables) • High MNC recovery (>85%) • High RBC depletion (>90%) • Fast processing time (40 minutes) • Closed system • 6 units processed during 1 centrifugation 15

  16. Slide 16: Res-Q Product Description

    Res-Q Res Q Product Description • Disposable, p , automated point-of-care p solution for preparation of cell concentrate from bone marrow • High MNC recoveries-greater than 80% in 6 cc’s of final product p • Simple procedure. Easy-to-learn and operate • Fast processing time (15 minutes) • Flexible f

  17. Slide 17: Celling Technologies Partnership

    Celling Technologies Partnership • Celling Technologies (a subsidiary of Spine Smith, LLC) utilizes MXP and Res-Q technology − Combines stem cell concentrates from bone marrow with proprietary implants to promote bone growth for spinal fusion • Strong in in-the-field the field results results—cell c

  18. Slide 18: Sales/Distribution Strategy

    Worldwide Distribution Sales/Distribution Footprint Strategy Product Distributor Region U.S. and Canada, and approximately 30 countries throughout GE Healthcare the world AXP System CEI 9 countries in Latin America Fenwal, Inc. China, India, Japan ThermoGenesis All other countries U.S. orthopedic in

  19. Slide 19: Product Pipeline

    Product Pipeline Fiscal Year PRODUCT 2009 2010 2011 2012 2013 MXP Res-Q: Q Bone Marrow Res-Q: PRP R&D/BUSINESS DEVELOPMENT Adipose Stem Cell Biomaterial Composites Concept Development Expected Phase Underway Revenue 19 Generation

  20. Slide 20: First Nine Months of Fiscal Year 2010 Financial Highlights

    First Nine Months of Fiscal Year 2010 g g Financial Highlights • First nine months of 2010 Revenues + 1% over prior i year same period i d • Disposable revenues + 14% over prior year same period • Continued vigilance over management of operating expenses • 8% reduction d i in i net loss l • $10 mill

  21. Slide 21: Fiscal Year 2010 Financial Outlook

    Fiscal Year 2010 Financial Outlook • 4Q 10 revenues to exceed $7 million, driven by market expansion p for AXP and continued rollouts of MXP and Res-Q Q • Quarterly operating expenses $2.5-$2.8 million • Achieve breakeven in 4Q 10 and profitability in 1Q 11 • Continue prudent management of balance s

  22. Slide 22: Fiscal Year 2010 Milestones

    Fiscal Year 2010 Milestones • Expand BioArchive System, AXP customer base • Fully penetrate Celling Technology Technology’s s customer base with MXP and Res-Q • Add new Res-Q distributors; expand applications beyond orthopedics • Product development activities in new markets markets, such as adipose

  23. Slide 23: Investment Considerations - KOOL

    Investment Considerations - KOOL • Growing adult stem cell market • Technology leader for collection/processing of stem cells from cord blood/bone marrow • Solid customer base (largest worldwide private, and largest U.S. public cord blood bank under contract) • Recent new product introductions in gr

  24. Slide 24: Thank You

    Thank You Thank You 24

ThermoGenesis — Investor Presentation (June 2010) on 6ix